How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Biologics Clinical Manufacturing CDMO Service Market
- By Service Type: Cell Line Development, Process Development, Analytical Development, Clinical Trial Material Manufacturing, Stability Studies, Regulatory Support
- By Therapeutic Modality: Monoclonal Antibodies, Recombinant Proteins, Cell Therapy, Gene Therapy, Vaccines
- By Manufacturing Scale: Preclinical Scale, Phase I Clinical Scale, Phase II Clinical Scale, Phase III Clinical Scale
- By Production Technology: Mammalian Cell Culture, Microbial Fermentation, Viral Vector Production, Suspension Culture, Adherent Cell Culture
- By End User: Pharmaceutical Companies, Biotechnology Companies, Academic and Research Institutions, Contract Research Organizations
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Cell Line Development leads By Service Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 303 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.183 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.191 →
Full report · locked preview
Everything inside the Biologics Clinical Manufacturing CDMO Service Market report
A complete, evidence-based study - 12 chapters and 127 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Service Type 6
Therapeutic Modality 5
Manufacturing Scale 4
Production Technology 5
End User 4
Companies profiled
Lonza Group
Samsung Biologics
Catalent Pharma Solutions
WuXi Biologics
Thermo Fisher Scientific
Sartorius Stedim Biotech
Boehringer Ingelheim BioXcellence
FUJIFILM Diosynth Biotechnologies
AGC Biologics
Cytiva
Baxter BioPharma Solutions
Recipharm
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Lonza Group
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Samsung Biologics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Catalent Pharma Solutions
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →WuXi Biologics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Thermo Fisher Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Sartorius Stedim Biotech
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Boehringer Ingelheim BioXcellence
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →FUJIFILM Diosynth Biotechnologies
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →AGC Biologics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Cytiva
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Baxter BioPharma Solutions
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Recipharm
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Siegfried Holding AG
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →KBI Biopharma
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Boehringer Ingelheim
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →
Global · 2025–2033
$2,586M by 2033 · 4.6% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Cell Line Development42.7
- Process Development14.8
- Analytical Development13.0
- Clinical Trial Material Manufacturing8.8
- Stability Studies7.8
- Regulatory Support12.9
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$593.9M → $932.5M · 5.8%
Europe$414.0M → $535.2M · 3.3%
Asia Pacific$378.0M → $517.2M · 4.0%
Latin America$234.0M → $324.5M · 4.2%
Middle East and Africa$180.0M → $257.2M · 4.6%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →4.582026
4.592027
4.612028
4.622029
4.632030
4.642031
4.672032
4.662033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Lonza Group14.0
- Samsung Biologics17.5
- Catalent Pharma Solutions8.2
- WuXi Biologics6.7
- Thermo Fisher Scientific10.9
- Sartorius Stedim Biotech14.7
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Service Type21.6%
Therapeutic Modality31.8%
Manufacturing Scale9.4%
Production Technology10.7%
End User26.5%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America36.3
- Europe20.9
- Asia Pacific20.1
- Latin America12.6
- Middle East and Africa10.0
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Lonza Group | 97 | 95 | 86 | 85 | 77 | 76 | 86 |
| Samsung Biologics | 89 | 70 | 80 | 88 | 92 | 69 | 81 |
| Catalent Pharma Solutions | 71 | 71 | 70 | 83 | 62 | 64 | 70 |
| WuXi Biologics | 68 | 78 | 72 | 79 | 57 | 58 | 69 |
| Thermo Fisher Scientific | 73 | 63 | 69 | 57 | 70 | 75 | 68 |
| Sartorius Stedim Biotech | 47 | 52 | 51 | 55 | 60 | 59 | 54 |
| Boehringer Ingelheim BioXcellence | 58 | 64 | 60 | 49 | 61 | 60 | 59 |
| FUJIFILM Diosynth Biotechnologies | 39 | 39 | 60 | 43 | 41 | 46 | 45 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Lonza Group
- Samsung Biologics
- Catalent Pharma Solutions
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Lonza Group | ✓ | ✓ | ✓ | ✓ | ◐ | ◐ |
| Samsung Biologics | ✓ | ✓ | ◐ | ✓ | ✓ | − |
| Catalent Pharma Solutions | − | ◐ | ✓ | ✓ | ◐ | ✓ |
| WuXi Biologics | ◐ | ◐ | ✓ | ◐ | ◐ | − |
| Thermo Fisher Scientific | ◐ | ◐ | ◐ | ◐ | ◐ | − |
| Sartorius Stedim Biotech | ◐ | ◐ | − | − | − | ◐ |
| Boehringer Ingelheim BioXcellence | − | ◐ | ◐ | − | ◐ | ◐ |
| FUJIFILM Diosynth Biotechnologies | − | − | ◐ | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Lonza Group86
2Samsung Biologics81
3Catalent Pharma Solutions70
4WuXi Biologics69
5Thermo Fisher Scientific68
6Boehringer Ingelheim BioXcellence59
7Sartorius Stedim Biotech54
8FUJIFILM Diosynth Biotechnologies45
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Lonza GroupSamsung Biologics
Challenger3
Strong scale, closing on the leaders.
Catalent Pharma SolutionsWuXi BiologicsThermo Fisher Scientific
Contender1
Focused players with pockets of strength.
Boehringer Ingelheim BioXcellence
Niche2
Specialists in a single segment or region.
Sartorius Stedim BiotechFUJIFILM Diosynth Biotechnologies
Go-to-market strategy
Land Service Type in North America, then scale across Biologics Clinical Manufacturing CDMO Service Market — a $286M beachhead inside a $5.67B market.
Beachhead (SOM)$286Mobtainable near-term
Serviceable (SAM)$2.00Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Cell Line Development
Best fit — highest urgency & budget in Service Type.
Economic buyer76 fit
Process Development
Strong fit — clear ROI and a fast path to value.
End user65 fit
Analytical Development
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Service Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Therapeutic Modality & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Manufacturing Scale
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel29%
Digital / self-serve17%
Marketplaces10%
Positioning & messaging
§GTM 2 · p.194 →For Service Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Biologics Clinical Manufacturing CDMO Service Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified43%
Sales qualified25%
Evaluation12%
Closed-won6%
$9.7KCAC
$40KLTV
4.1:1LTV : CAC
< 3 moCAC payback
Investment thesis
Biologics Clinical Manufacturing CDMO Service Market is a durable-growth opportunity — $9.13B by 2033, compounding at 7.8%.
TAM · 2025$5.01Btoday
TAM · 2033$9.13Bforecast
CAGR7.8%2027–2033
Cumulative$62.0Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$9.13BTotal addressable market
SAM$3.38BServiceable available market
SOM$663MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →7.8% CAGR
Demand compounds through 2033, outpacing GDP across Service Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Service Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$9.13BLarge & growingTAM by 2033 at 7.8% CAGR
$3.38BServiceable nowreachable with today’s model
$663MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$7.12BBear5.1% CAGR
$9.13BBase7.8% CAGR
$11.7BBull10.3% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Therapeutic Modality optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Biologics Clinical Manufacturing CDMO Service Market — a $6.86B market by 2033. Plan: grow share from 7.3% to 15.7%.
Market size · 2033$6.86Btotal addressable
Market CAGR5.6%2027–2033
Target share15.7%from 7.3% today
Revenue ambition$1.08Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.3% | 15.7% | At risk |
| Revenue | $477M | $1.08B | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 31.8% | 39.3% | On track |
| Customer retention | 91.1% | 96.2% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Service Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Therapeutic Modality capability
A defensible second engine — invest in Therapeutic Modality to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Service Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Therapeutic Modality
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $118M capacity & capability investment
- Greenlight bolt-on M&A in Therapeutic Modality
- Authorise North America expansion plan
- Fund R&D program for Service Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossAt risk
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentAhead
Sales deck · value proposition
Win the Biologics Clinical Manufacturing CDMO Service Market conversation — a $2.47B market you can size, segment and defend in minutes.
Market size · 2033$2.47Btotal opportunity
Growth5.8%CAGR to 2033
Addressable buyers1,639+accounts in scope
Typical ROI7×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Service Type
Goal Grow share in Service Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7×return on cost, year one
< 3 mopayback period
$94K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Lonza GroupSamsung BiologicsCatalent Pharma SolutionsWuXi BiologicsThermo Fisher ScientificSartorius Stedim BiotechBoehringer Ingelheim BioXcellenceFUJIFILM Diosynth Biotechnologies+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Biologics Clinical Manufacturing CDMO Service Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Biologics Clinical Manufacturing CDMO Service Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Biologics Drug Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportBiologics Fill Finish CDMOs Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportBiologics for Animal Health Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportBiologics Manufacturing Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportBiomarker (Medicine) Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportBiomarkers Validation and Testing Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportBiomass Briquette & Pellets Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportBiomass Briquette Boiler Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportBiomass Briquettes and Pellets Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportBiomass Briquetting Feed Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportBiomass Briquetting Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportBiomass Curing Equipment Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report ships as a formatted PDF, a fully editable XLSX containing all underlying data tables, and a presentation-ready PPT deck - so you can re-chart, re-model, or drop any figure straight into your own deck.